- Home
- BME vs VSTM Comparison
BME vs VSTM Comparison
Compare BME & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BME
- VSTM
- Stock Information
- Founded
- BME 2005
- VSTM 2010
- Country
- BME United States
- VSTM United States
- Employees
- BME N/A
- VSTM N/A
- Industry
- BME Trusts Except Educational Religious and Charitable
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- BME Finance
- VSTM Health Care
- Exchange
- BME Nasdaq
- VSTM Nasdaq
- Market Cap
- BME 486.1M
- VSTM 581.6M
- IPO Year
- BME N/A
- VSTM 2012
- Fundamental
- Price
- BME $39.89
- VSTM $7.70
- Analyst Decision
- BME
- VSTM Strong Buy
- Analyst Count
- BME 0
- VSTM 9
- Target Price
- BME N/A
- VSTM $13.38
- AVG Volume (30 Days)
- BME 34.0K
- VSTM 2.8M
- Earning Date
- BME 01-01-0001
- VSTM 11-04-2025
- Dividend Yield
- BME 6.26%
- VSTM N/A
- EPS Growth
- BME N/A
- VSTM N/A
- EPS
- BME 1.44
- VSTM N/A
- Revenue
- BME N/A
- VSTM $13,379,000.00
- Revenue This Year
- BME N/A
- VSTM $88.60
- Revenue Next Year
- BME N/A
- VSTM $416.99
- P/E Ratio
- BME $28.37
- VSTM N/A
- Revenue Growth
- BME N/A
- VSTM 33.79
- 52 Week Low
- BME $35.53
- VSTM $3.46
- 52 Week High
- BME $43.20
- VSTM $11.25
- Technical
- Relative Strength Index (RSI)
- BME 67.41
- VSTM 41.32
- Support Level
- BME $37.91
- VSTM $7.55
- Resistance Level
- BME $40.70
- VSTM $8.86
- Average True Range (ATR)
- BME 0.43
- VSTM 0.60
- MACD
- BME 0.15
- VSTM -0.07
- Stochastic Oscillator
- BME 66.98
- VSTM 14.64
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.